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Abstract
Background: Celiac disease (CD) is an autoimmune gastrointestinal disorder characterized by the presence of anti-
transglutaminase 2 (TG2) and anti-gliadin antibodies. Amongst the neurological dysfunctions associated with CD, ataxia
represents the most common one.
Methods: We analyzed by immunohistochemistry, the anti-neural reactivity of the serum from 20 CD patients. To determine
the role of anti-TG2 antibodies in ataxia, two anti-TG2 single chain variable fragments (scFv), isolated from a phage-display
IgA antibody library, were characterized by immunohistochemistry and ELISA, and injected in mice to study their effects on
motor coordination. We found that 75% of the CD patient population without evidence of neurological involvement, has
circulating anti-neural IgA and/or IgG antibodies. Two anti-TG2 scFvs, cloned from one CD patient, stained blood vessels but
only one reacted with neurons. This anti-TG2 antibody showed cross reactivity with the transglutaminase isozymes TG3 and
TG6. Intraventricular injection of the anti-TG2 or the anti-TG2/3/6 cross-reactive scFv provoked transient, equally intensive
ataxia in mice.
Conclusion: The serum from CD patients contains anti-TG2, TG3 and TG6 antibodies that may potentially cause ataxia.
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Introduction
Gluten sensitive enteropathy or celiac disease (CD) is a common
(1 in 90) state of heightened immunological responsiveness to the
ingestion of gluten in genetically predisposed individuals having
the HLA class II haplotype DQ2 or DQ8 [1]. The clinical
spectrum of CD ranges from asymptomatic to the classic
malabsorption syndrome [2]. In addition, a variety of neurological
manifestations have been identified, including ataxia [3], epilepsy
[4], brain atrophy, headache with white matter lesions and
polyneuropathy [5].
The serum from patients with CD contains characteristic
antibodies against the self antigen, tissue transglutaminase (TG2)
[6] as well as against gliadin, the most abundant gluten protein. In
addition, in the effector phase of the disease the epithelium of the
small intestine contains infiltrates of TCRab+ CD8+ T cells
proportional to the tissue damage [7,8,9]. Furthermore, other
autoimmune diseases are often present in patients with CD or their
first-degree relatives sharing the same HLA haplotype [10].
It has been hypothesized that ataxia seen in the context of
gluten sensitivity, also called gluten ataxia, might be caused by an
autoimmune mechanism. This hypothesis is supported by the
finding that in some patients IVIg therapy succeeded [11,12,13]
and that serum from patients with gluten ataxia reacts with
Purkinje cells. This reactivity has been attributed in part to
circulating anti-gliadin antibodies and in part to other, yet
unidentified, antibodies [14]. A pathogenic role of these antibodies
is suggested by the fact that intraventricular injections of serum
from patients with gluten ataxia cause a transient ataxia in mice.
Injection of sera from patients with CD without neurological
complications however, has similar effects [15]. These data suggest
that serum antibodies from CD patients might have an intrinsic
potential to induce ataxia, and possibly neurodegeneration, when
they enter the CNS.
Anti-TG2 antibodies, the specific marker of CD, are primarily
deposited locally in the intestine but they have also been found
in liver, muscle and lymph nodes [16]. Recent studies also
demonstrated intrathecal production of anti-TG2 antibodies
in patients with neurological disease [17] and the presence of
perivascular IgA deposits in the cerebellum of patients with
gluten ataxia [18]. In the present study we investigated whether
differential reaction of patient-derived anti-TG2 antibodies [8]
with cerebellar neurons could explain the development of
ataxia.
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Sera
Sera were collected in the Transfusional centre of the IRCCS
Burlo Garofolo Hospital of Trieste following written informed
consent and approval by the Scientific Directorate. The
investigation was approved by the Local Ethical Committee. Sera
from twenty CD patients with no known neurological complica-
tions were collected at diagnosis of CD (mean age 35.4 yr; range
20–61 yr) and 20 donor sera were used as healthy controls (mean
age 35.4 yr; range 23–60 yr). All CD patients sera were positive
for anti-TG2, anti-gliadin and anti-EMA antibodies.
Anti-TG2 and anti-gliadin antibodies were measured with Eu-
tTG or Alpha-gliatest kits (Eurospital, Trieste, Italy) respectively.
Anti-endomysium antibodies (EMA) and islet cell autoantibodies
(ICA) were detected by immunohistochemistry. Antibodies to
mitochondrial antigens (AMA), to smooth muscle antigens (SMA)
and to nuclear antigens (ANA) were detected with the Alphadia
autoscreen II test system (Axis-Shield, Cambridgeshire, UK).
Animals
Animals were housed at the University animal house according
to institutional guidelines, and all animal work was approved by
the Institutional Review Committee for Animal Studies of the
University of Trieste in accordance with national (DL N116, GU,
suppl 40, 18-12-1992) and international laws and policies
(European Community Council Directive 86/609, December 12,
1987). Animals were purchased from Harlan Italy (San Pietro al
Natisone, Italy), kept in individual cages in the Animal Facility of
the University of Trieste in a controlled environment (T=22uC,
12-/12-hour light/dark cycle), and fed a standard commercial
chow diet (Harlan 2018, 3.4 kcal/g; Harlan). At the end of
experiments animals were CO2 sacrificed, brains were immedi-
ately frozen in isopenthane/dry ice and stored at 280uC.
Selection and purification of scFvs
Single chain (scFv) antibodies to TG2 were selected from a
phage display antibody library on recombinant human TG2 (h-
TG2) and based on analysis of reactivity with different TG2
fragments assigned to one of two groups named class1 and class2
[8]. cDNA amplification in library construction employed primers
specific for cH1 heavy chain and the resulting library is con-
sequently representative of a specific Ig class [19], IgA in this case.
The control scFv named bac1 was selected against an unrelated E.
coli protein from a large naı ¨ve scFvs library [20]. The scFvs are
made up of linked vL and vH and contain both an His6 and a SV5
[21] tags. ScFv antibodies were purified by Ni-NTA chromatog-
raphy (Qiagen, Milano, Italy), dialyzed against PBS and diluted to
a final concentration of 0.1 mg/ml.
Immunohistochemistry
Immunohistochemistry and densitometry on rat brain sections
were carried out as previously described [22]. Immunohistochem-
istry was also performed on wild type and TG2
2/2 C57Bl/6 male
mice brains with both sera and monoclonal anti TG2 antibodies.
Purified scFv antibodies (1:1) were revealed with a secondary
mouse anti-SV5 tag (1:1) [21] and a tertiary HRP-conjugated anti-
mouse IgG (1:200, Jackson Immunoresearch labs, Suffolk, UK).
TG2 was also detected with monoclonal antibody CUB7402
(LabVision, Cheshire, UK), (1:1000). For preadsorption experi-
ments, sera (1:100 for IgA; 1:600 for IgG) were incubated with
10 mg/ml of recombinant h-TG2, or 50 mg/ml of BSA as negative
control, for 30 min at room temperature before use for
immunohistochemistry.
ELISA
Brain homogenates were prepared from C57Bl/6 wt, TG2
2/2
mice, Sprague-Dawley rats, and an adult human Caucasian male
in a tissue lysis buffer (25 mM TrisHCl pH 7.5, 1 mM EDTA,
1 mM spermidine, 1 mM phenylmethylsulfonylfluoride, 1 mM
iodoacetamide, 1 mM soy bean trypsin inhibitor, 10 mg/ml turkey
egg white inhibitor and 0,1%Triton X100). Antigens (brain
homogenates or recombinant human TG2 [23], TG3 or TG6
[24] were diluted in PBS to 10 mg/ml immediately before use.
Multi well strips (Costar, Corning Incorporated, NY, USA) were
coated with 100 ml/well of the antigen solution (16 h, 4uC),
washed with PBS containing 0.1%Tween20 and blocked with
200 ml/well of 2% skimmed milk in PBS for 1 h at room
temperature. Strips were incubated for 1 h with scFvs (60 mg/ml),
then with mouse anti-SV5 tag antibody [21] (1:200) and finally
with HRP-conjugated anti-mouse IgG (Jackson Immunoresearch
labs, Suffolk, UK) (1:1500). All antibodies were diluted in blocking
solution (100 ml/well). Development was carried out with 1-step
turbo TMB (Pierce, Rockford, Illinois, USA) and absorbance read
at 450 nm.
Motor coordination tests
Adult C57Bl/6 male mice were trained as described in
supplemental material (Text S1) for motor coordination test on
rotarod and their performance was subsequently evaluated
following injection with scFvs.
Footprint analysis was performed on mice 5 h after injection
with control or anti TG2 scFv antibodies class1 or class2. Atoxic
and aqueous colors have been used (blood red and ultramarine
blue, Citadel Paint)to paint paws. Mice instinctively run towards a
closed box situated at the end of a corridor (50 cm length610 cm
width) where a white paper is placed. Three test for each mouse
were carried out and four different parameter considered: R-L
forelimb stride and R-L hindlimb stride, frontbase, hindbase and
finally R-L overlap. Four (class1 and bac1) or six (class2) mice for
each injected antibody were tested and data considered only after
detection of correct incannulation position with haematoxylin-
eosin staining.
Statistics
For comparison of reactivity of class1 or class2 scFvs on TG3 or
TG6 in ELISAs, and for footprint analysis, one way ANOVA was
used. For comparison between class1 or class2 scFv effect on mice
balance for motor coordination test the Wilcoxon test was used.
Localization of injected scFv
The purified scFvs class1, class2 or bac1 were biotinylated
following the manufacturer’s instructions (Pierce, Rockford,
Illinois, USA), and 3 ml (100 ng/ml in PBS) were injected
intraventricularly in mice. Three hours after injection mice were
sacrificed. Cryosections of brains were fixed and endogenous
peroxidase blocked with 0.3% H2O2 in methanol for 7 min, 0.3%
H2O2 in 96% ethanol for 3 min, rehydrated in 0.3% H2O2 in
70% ethanol for 2 min, and rinsed with H2O and PBS.
Biotinylated scFv was detected with HRP-conjugated streptavidin
(1:60,000 in PBS) (Pierce, Rockford, Illinois, USA) and revealed
with the chemiluminescent detection system (ECL GE Healthcare,
Milan, Italy). After injection, biotinilated scFvs were detected with
FITC-conjugated streptavidin (1:100 in PBS containing
0.05%Tween20) (Dako, Milano, Italy). Blood vessels were stained
with anti-Von Willebrand factor (vWF) (1:500 in PBS containing
0.05%Tween20) (Dako, Milano, Italy) followed by anti-rabbit
conjugated with TRITC (1:30 in PBS containing 0.05%Tween20)
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group).
Results
Clinical data
All 20 CD patients were positive for anti-TG2, EMA and AGA
antibodies, were HLA-DQ2 or DQ8 positive and the intestinal
biopsy showed villous atrophy, crypt hyperplasia and increased
intraepithelial lymphocytes, in keeping with CD. Serological
analysis for other autoimmunity markers (ICA, AMA, SMA,
ANA) were negative. Healthy donors were negative for all
autoantibodies tests and had no relatives presenting with
autoimmune disorders.
Anti-neural autoantibodies in patients with CD
Sera were tested for anti-neural immunoreactivity on rat brain
sections by immunohistochemistry. Only three out of 20 healthy
blood donor sera were positive (1 for both IgA and IgG, 2 for IgG
only). Figure 1 shows a typical result for detection of IgA
(Figure 1A, B, C) and IgG (Figure 1D, E, F), from a healthy subject
on rat Purkinje cells, deep cerebellar nuclei and brainstem
neurons. In contrast, 4 out of 20 patients with CD showed strong
anti-neural IgA reactivity (Figure 1G, H, I) and 12 out of 20 had
abundant immunoreactive IgG (Figure 1J, K, L). The most
frequent staining pattern of sera from CD patients was
characterized by a weak cytoplasmic and a strong perinuclear
labeling (Figure 1G-L; Figure S1, CD1 and CD2). Sera from two
patients stained only the cytoplasm when detecting IgG (Figure S1,
CD3).
Role of the anti-TG2 antibodies in neuronal reactivity of
CD patient sera
Since the development of anti-TG2 autoantibodies is charac-
teristic of CD and neuronal expression of TG2 has been
demonstrated [25], we investigated if these antibodies contributed
to the anti-neural reactivity detected in CD patient sera. Sera from
two randomly selected patients with CD and anti-neural
antibodies, were preadsorbed with recombinant h-TG2. Elimina-
tion of anti-TG2 antibodies was demonstrated by the absence of
staining on rat esophagus sections for both IgA (Figure 2A, B) and
IgG (data not shown) with the adsorbed sera. Comparison of the
Figure 1. Reactivity of rat brain sections with serum IgAs and IgGs of CD patients. Immunohistochemical staining on rat Purkinje cells (left
panels, arrow heads), deep cerebellar nuclei neurons (middle panels, arrow head) and brainstem reticular neurons (right panels) using either serum
from a healthy donor (A–F) or from an untreated CD patient (G–L). No binding of serum IgAs (A–C) and IgGs (D–F) from healthy donors could be
detected. In contrast, antibodies in sera of CD patient (positive for anti-TG2 IgA/IgG antibodies) stained the cytoplasm and the perinuclear zone of
neurons from the three brain areas, both when detecting IgAs (G–I) or IgGs (J–L). Calibration bars=20 mm.
doi:10.1371/journal.pone.0009698.g001
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and after adsorption (Figure 2D), showed nearly complete
elimination of the reactivity, both at the cytoplasmic and
perinuclear level. In contrast, serum preadsorption produced a
significant reduction of the cytoplasmic binding of IgG but the
perinuclear staining persisted (Figure 2E, F). These data suggest
that in patients with CD, anti-TG2 antibodies substantially
contribute to the recognition of neuronal epitopes. However,
anti-TG2 IgG class antibodies account for only part of the anti-
neural IgG-related reactivity.
Since anti-neural IgA reactivity of patients with CD was entirely
due to anti-TG2 antibodies, two different types of anti-TG2 scFvs
(class1 and 2) were employed that had been affinity selected using
recombinant h-TG2 from an IgA phage display library of
intestinal lymphocytes of CD patients [8]. These class1 and class2
anti-TG2 scFvs appear to be representative of two distinct patterns
of Ig reactivity with TG2 typically seen, i.e. recognize distinct
epitopes of TG2 that are commonly targeted in CD [8,26]. scFvs
belonging to class1 and the well characterized anti-TG2
monoclonal antibody CUB7402 recognize human, mouse and
guinea pigTG2 whereas class2 scFv reacts only with human-TG2
(Figure S2) [8].
In immunohistochemistry, class1 anti-TG2 scFv strongly stained
rat esophagus, the tunica adventitia of brain and cerebellum blood
vessels and the choroid plexus but was negative on neurons
(Figure 3A–E). In contrast, class2 showed faint staining on rat
esophagus (Figure 3F) but strongly labeled neurons and the tunica
media of brain and cerebellum blood vessels with a staining
pattern distinct from that of class1 (Figure 3G, I, J). Both anti-TG2
scFvs labeled microvessels in brain (Figure 3C, H) and cerebellum.
The antibody CUB7402 gave the same staining pattern as class1
on rat tissues (Figure 3K–O) whereas a control scFv was negative
(Figure 3P–T). Identical results were obtained on mouse and
monkey brain sections (data not shown) suggesting that the faint
staining of class2 scFv on TG2-rich tissues (Figure 3F) is likely to
relate to its poor affinity for TG2 of species other than human.
These results were further supported by ELISA experiments,
where class2 scFv not only strongly reacted with mouse and rat but
also human brain homogenates while the class1 and control scFvs
were at background level (Figure 3U). Some reaction of class1 on
brain lysates was expected because of its reactivity with vessels in
immunohistochemistry (see Figure 3B,C). However, the mild
conditions under which the tissue was extracted were likely not
able to efficiently solubilise extracellular matrix-bound perivascu-
lar TG2.
Class2 anti-TG2 IgA crossreacts with other
transglutaminases
The observed differences in reactivity with tissue structures
could relate to selective availability of TG2 epitopes due to
alternative splicing [27] or distinct conformations adopted by the
protein upon binding of nucleotides or Ca2+ ions, respectively
[28] but could also relate to epitopes shared between different
types of transglutaminases. Class2 scFv reacted strongly with brain
homogenate from TG22/2 mice (Figure 3U) indicating that this
antibody can cross-react with an antigen other than TG2.
Immunohistochemistry on TG2
2/2 mouse brain sections con-
firmed the absence of reactivity with class1 scFv (in blood vessels)
while class2 scFv showed a similar anti-neural staining pattern to
that seen in wildtype brain (Figure S3).
As a number of transglutaminases have been detected in brain
[24,27,29,30], and all members of the transglutaminase family
have a high degree of sequence similarity, we tested whether the
scFvs cross reacted with the TG3 and TG6 which are the isoforms
most closely related to TG2, both in terms of amino acid sequence
and protein activities [31]. Notably TG3 is involved in another
gluten sensitive disease (dermatitis herpetiformis) and TG6 is
suspected as a possible autoantigen in the neurological manifes-
tations of gluten sensitivity [24]. In ELISA with immobilized
recombinant human TG2, TG3 or TG6, class1 scFv reacted only
Figure 2. Adsorption of CD serum antibodies on recombinant
human TG2 reduces substantially the recognition of neuronal
epitopes. Immunohistochemical staining on rat esophagus and
brainstem neurons with CD patient serum before (A, C, E) and after
depletion of anti-TG2 autoantibodies (B, D, F). Both IgAs (A) and IgGs
(not shown) labeled rat esophagus in a pattern reminiscent of that of
TG2 distribution in the tissue. The patient’s serum also labeled rat
neurons in the brainstem (C, IgAs; E, IgGs) with a strong perinuclear
staining. After adsorption on recombinant human TG2, no IgA binding
to rat esophagus sections could be detected (B). On rat neurons, TG2
adsorption eliminated the IgA reactivity both at the cytoplasmic and
nuclear level (D, arrowheads) while the IgG staining was reduced at the
cytoplasmic level but remained almost unaltered in the perinuclear area
(F, arrowheads). Calibration bars=20 mm.
doi:10.1371/journal.pone.0009698.g002
Autoantibodies in Ataxia
PLoS ONE | www.plosone.org 4 March 2010 | Volume 5 | Issue 3 | e9698with TG2, while class2 also bound to TG6 and TG3, although to a
lesser extent as compared to TG2 (Figure 4). Thus, class1
represents a pure anti-TG2 IgA while class2 scFv turned out to be
from an anti-TG2-3-6 IgA.
Effects of anti-TG2 IgA antibodies on mouse motor
coordination
We investigated if such anti-TG2 antibodies have a direct
causative role in ataxia by injecting the anti-TG2 (class1), the anti-
TG2-3-6 (class2) or the control (bac1) scFv into the lateral ventricle
of mice and tested their effect on balance using the rotarod test [15].
We demonstrated that mice treated with either class1 or class2 scFv
manifested a dramatic motor impairment at 3 h and 6 h after
injection, as compared to the preinoculum performance (Figure S4).
Symptoms of motor dysfunction disappeared at 24 h post-injection.
As expected, the performance of mice treated with the control scFv
was not affected (Figure S4). We also tested mice ataxic gait with
footprint analysis. R-L overlap demonstrated clear motor impair-
ment in mice treated with anti-TG2 (Figure 5F–G, arrowheads) but
not with control scFv (Figure 5E, arrows). In particular mice
injected with anti-TG2 class1 exhibited a significant shorter
forelimb stride length and a less marked hindlimb stride length
Figure 3. Distinct staining patterns of CD patient derived class1 and class2 IgA scFvs to TG2 on rat esophagus and brain sections.
The class1 anti-TG2 scFv strongly labeled rat esophagus (A), with the reticular staining pattern typical for TG2, the tunica adventitia of brain and
cerebellum vessels (B) and to a lesser extent brain and cerebellum capillaries (C) but did not recognize brain neurons (D, E). In contrast, the class2
anti-TG2 scFv showed a very faint and diffuse labeling on esophagus sections (F) but strongly labeled the tunica media of brain and cerebellum
vessels (G), recognized brain and cerebellar microvessels (H) and also neurons including Purkinje cells (I) and brainstem neurons (J). The monoclonal
anti-TG2 antibody CUB7402 reacted on rat tissues with a pattern that is reminiscent of the staining pattern of class1 scFv (K–O). Bac1, a non relevant
scFv used as negative control, showed no labeling on rat esophagus (P) brain vessels (Q, R) or neurons (S, T). Calibration bars=10 mm for C, H, M, R
40 mm for B, G, L, Q and 20 mm for the others. To confirm their specificity, the scFvs were also tested in ELISA on different brain homogenates and on
human recombinant TG2. As expected, both class1 and class2 scFvs recognized TG2. However, only the class2 scFv reacted with an epitope in human
and rat brain extracts. This epitope was present in brain lysates from wt or TG2
2/2 mice suggesting that it is not TG2. Bac1 was negative on each
substrate used for coating (U).
doi:10.1371/journal.pone.0009698.g003
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significant difference between mice treated with class1 or bac1 was
found for the hind and front-base width (Figure 5I) while mice
treated with class1 displayed a greater distance between fore/
hindpaw overlap compared to that produced bac1 injected mice
(Figure 5J). Mice injected with scFv class2 showed indistinguishable
forelimb and hindlimb stride length from those produced by bac1
(Figure 5H), but showed a mild decrease in the fore and hind-base
width (Figure 5I) and a significant different overlap measurement
compared to bac1-injected mice (Figure 5J).
To confirm effective delivery of the antibodies into the lateral
ventricles and to investigate their interaction with CNS tissue,
biotinylated scFvs were injected, 3 h later brains dissected, and
scFvs detected on sections using streptavidin. Horizontal brain
sections from untreated mice, incubated with streptavidin-
peroxidase alone, showed no labeling above background
(Figure 5A). Sections from mice treated with the biotinylated
class1, class2 or bac1 scFv clearly demonstrated the presence of the
injected scFv within the lateral ventricles (Figure 5B, C, D
asterisk), to a lesser extent in the collicoli (Figure 5B, C, D
arrowhead), in the cerebellum (Figure 5B, C, D arrow), and also
revealed infiltration of the scFv into the brain parenchyma. Since
both class1 and class2 scFvs provoked motor impairment in mice
and both labeled blood vessels in the brain, we hypothesized that
they could bind at the level of the brain vasculature. To determine
if the injected scFvs antibodies were able to localize on brain
vessels, streptavidin-FITC was used and vessels were stained with
anti-vWF revealed with anti-rabbit-TRITC. The vWF is a protein
produced by endothelial cells at the inner layer of the blood vessels
and is accumulated in storage granules in the cytoplasm of these
cells. Confocal images show localization of both class1 and class2
on vessels structures (Figure 6A, B) and confirmed our finding that
the two scFv classes have a distinct staining pattern, with class1
binding the more external layers and class2 the more internal
layers. No localization of bac1 was detected on vessels (Figure 6C)
while it was clearly present in the ventricle (data not shown) as also
shown by chemiluminescence (Figure 5D). Haematoxylin and
eosin staining of brain sections of each animal demonstrated
absence of inflammation (data not shown).
Discussion
Autoantibodies are a characteristic feature of CD and are
thought to contribute to extraintestinal organ involvement within
the spectrum of gluten sensitivity. We tested their potential role in
the production of neurological deficits and whether a link exists
between anti-TG2 antibodies and the neural reactivity of sera.
We found that i) 75% of the CD patient population (without
evidence of neurological involvement) has circulating anti-neural
IgA and/or IgG antibodies; ii) anti-neural reactivity of serum IgA
reflects the presence of anti-TG2 antibodies (belonging to class2),
that also cross-react with TG3 and TG6; iii) anti-neural reactivity of
serum IgG appears to be determined only in part by the presence of
anti-TG2 antibodies; and interestingly, that iv) both TG2-specific
(class1) as well as anti-TG2 antibodies crossreacting between TG
isozymes (class2) cause ataxia in mice when directly administered to
the CNS. This indicates that potentially pathogenic antibodies
targeting antigens in the CNS are a common feature among CD
patients but that their presence alone is unlikely to be the only event
that precipitates into a pathological state. A role for anti-TG
antibodies in causing ataxia, however, is strongly indicated by the
fact that the control scFv has no effect whereas two different anti-
TG2 scFvs produce the same functional deficit in mice. As scFvs do
not bear the Fc sequence, these results clearly demonstrate that
there is no requirement for complement activation or Fc receptor
engagement for induction of motor coordination deficits.
Class1 anti-TG2 recognizes both human and rodent TG2
[8,26,32] while the class2 scFv recognizes human but not guinea
pig [8,20,26] or mouse TG2 [33]. Therefore, it is unlikely that in
mice, class2 can exert its effect by reacting with TG2. This is
further supported by the fact that class2 scFv reacted with epitopes
in the brain from TG22/2 mice and recognized recombinant
TG3 and TG6 in ELISA, albeit with lower affinity as compared to
human TG2. We therefore hypothesize that cross-reaction with
Figure 4. Cross reactivity of class2 but not class1 scFv with different TGases. Anti TG2 scFvs were tested in ELISA on human recombinant
TG3 or TG6 as an antigen to determine whether they recognize an epitope that is shared between different TG isozymes. Class2 scFv is reactive with
both TG3 and TG6 (P,0,001 *** one way Anova) in contrast to class1 which reacts exclusively with TG2.
doi:10.1371/journal.pone.0009698.g004
Autoantibodies in Ataxia
PLoS ONE | www.plosone.org 6 March 2010 | Volume 5 | Issue 3 | e9698TG3 or TG6 may be responsible for the same pathogenic effect in
the animal model.
Although identification of the mechanisms through which anti-
TG2 antibodies cause ataxia was beyond the scope of the present
study, our findings that both class1 and class2 scFvs labeled
cerebrum and cerebellar blood vessels in immunohistochemistry
and that they localized on vessels after injection in the lateral
ventricle of brain, suggest that these antibodies may cause ataxia
through an antibody-antigen interaction at the vascular level. This
hypothesis is supported by three recent findings, firstly TG1 [34],
Figure 5. Localization of anti-TG2 scFvs after intraventricular delivery and footprint analysis. The effective delivery of the scFvs after
injection, was confirmed on transverse brain sections by detection of the injected biotin conjugated scFvs with streptavidin conjugated horseradish
peroxidase. Sections of untreated mice incubated with streptavidin-peroxidase alone showed no discrete labeling (A) whereas sections from mice
injected with biotinylated class1 (B), class2 (C) or bac1 (D) scFv clearly demonstrated the presence of these in the lateral ventricles of mice 3 h after
injection (asterisks) and in the brain parenchyma even at considerable distance from the ventricles (cerebellum, long arrows; collicoli, short arrows).
Mice treated with monoclonal antibodies were tested at 5 h, after antibody injection for gait imbalance with footprint analysis. The R-L overlap clearly
demonstrated that the control scFv bac1 had no effect on mice gait (E, arrows, front paws colored with red, back paws colored with blue), on the
contrary with both class1 and class2 there was no overlap between left or righ front and back paws (F–G, arrowheads). In particular, four step
parameters have been recorded, namely, stride length (H), front and hind-base width (I) and overlap between forepaw and hindpaw placement (J).
Mice injected with anti-TG2 monoclonal antibody class1 exhibited a significant shorter forelimb stride length and a less marked hindlimb stride
length (H) compared to mice treated with the negative control monoclonal antibody bac1. There was no significant difference between mice injected
with class1 or bac1 for the hind and front-base width (I) while mice treated with class1 displayed a greater distance between fore/hindpaw overlap
compared to that produced by negative control injected mice (J). Mice injected with monoclonal antibody class2 showed indistinguishable forelimb
and hindlimb stride length from those produced by negative control mice (H) a little decrease in the fore and hind-base width (I) while showed a
significant different overlap measurement compared to the negative control mice (J). Bars represent the mean value of each measurement
considered, n is the number of mice injected with the monoclonal antibodies. Error bars represent SE. uuu P=0,002 one way ANOVA class 1 compared
to bac1. *** P,0,001 one way ANOVA class 1 compared to bac1 or class 2 compared to bac1.
doi:10.1371/journal.pone.0009698.g005
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capillaries, secondly, TG1 [34] and TG2 [35] play a role in
controlling both blood vessel diameter and permeability, and
thirdly, anti-TG2 antibodies from CD patients disturb angiogen-
esis in vitro [38]. Our finding that serum IgA from patients with CD
strongly reacted with rat brain blood vessels, is in agreement with a
previous study carried out on a smaller group of patients [39]. We
have previously shown that such IgA antibodies are deposited in a
perivascular distribution in the cerebellum of a patient with gluten
ataxia [18]. However, it is not clear at present whether
autoantibody accumulation is a consequence of a breached
blood–brain barrier or the mediator of such a breach.
The fact that mice show functional deficits rapidly after anti-
TG2 scFv administration in the absence of any detectable
inflammatory cell infiltration in the CNS suggests an antibody
mediated mechanism. Induction of localized vascular permeability
is also more consistent with the observed partial reversibility of the
functional deficit. However, it remains to be determined whether
prolonged antibody exposure can ultimately cause neuronal
degeneration.
Anti-TG2 antibodies are found in at least 98% of patients with
CD [26,40] but only a proportion of them develop neurological
deficits. Although the reason for this remains unclear, a
particularly intriguing result of this study is that the vast majority
of CD patients without clinically manifest CNS involvement have
circulating antibodies that react with epitopes on neurons.
However, while only 20% of CD patients had IgA reactive with
neurons, 60% had IgG reactive with neurons. Preadsorption of
sera on TG2 revealed a residual IgG reactivity to neurons
suggesting that IgG antibodies targeting other neural antigens are
present, consistent with previous reports identifying anti-GAD
IgGs [41]. Thus, anti-TG antibodies may act in concert with
further autoantibodies to cause selective neuronal degeneration.
In conclusion, anti-neural reactivity in CD patients is linked to
the presence of class2 anti-TG2-TG3-TG6 antibodies that are
able to cause ataxia. Consequently, immunohistochemistry on rat
brain sections to identify CD patients with anti-neural reactivity
may help identifying a subgroup of patients with a specific risk to
develop neurological disorders. However, exposure of the CNS to
anti-TG2 that do not cross react with neurons can also cause
ataxia. Thus, it remains to be seen whether class2 antibodies are
strictly associated with patients with neurological deficits and
whether in long-term follow-up the development of such anti-
bodies can be linked to a higher risk of developing neurological
complications.
Supporting Information
Figure S1 This figure represents the most frequent staining
pattern of sera from various CD patients characterized by a weak
cytoplasmic and a strong perinuclear labeling (CD1 and CD2).
Sera from two patients stained only the cytoplasm when detecting
IgG (CD3).
Found at: doi:10.1371/journal.pone.0009698.s001 (6.16 MB TIF)
Figure S2 Reactivity of monoclonals anti-TG2 on TG2 from
various species. Class1 scFv and the commercial CUB7402
recognize human, mouse and guinea pig TG2 whereas class2
scFv reacts only with human-TG2.
Found at: doi:10.1371/journal.pone.0009698.s002 (1.86 MB TIF)
Figure S3 Immunohistochemistry on TG22/2 mouse brain
sections with patient’s serum, class1 or class2 scFv anti-TG2.
Immunohistochemistry confirmed the absence of reactivity with
class1 scFv (in blood vessels) while class2 scFv showed a similar
anti-neural staining pattern to that seen in wildtype brain.
Found at: doi:10.1371/journal.pone.0009698.s003 (4.38 MB TIF)
Figure S4 Motor coordination test on the rotarod after
intraventricular delivery of anti-TG2 scFvs. Mice treated with
monoclonal antibodies were subjected to three rotarod trials
(9 rpm) before the intraventricular injection (Pre in.), and were
tested at 1 h, 3 h, 6 h, 24 h after antibody injection. The mean
latency to fall (maximum trial duration=120 sec) of the three
trials was recorded. Mice treated with anti-TG2 class1 or class2
scFvs exhibited significant impairment of the balance on the
rotarod at 3 h and 6 h after injection. Mice treated with the
control antibody bac1 showed no decline in performance. (n=
numberofanimals;errorbarsrepresentSEM;**P,0.01,*P,0.05,
Wilcoxon test)
Found at: doi:10.1371/journal.pone.0009698.s004 (2.69 MB TIF)
Text S1
Found at: doi:10.1371/journal.pone.0009698.s005 (0.03 MB
DOC)
Figure 6. Localization of anti-TG2 scFvs after intraventricular delivery on small brain vessels. Biotinylated scFvs were revealed 3 h after
injection by incubating FITC-conjugated streptavidin on brain sections. Brain vessels were stained with anti-von Willebrand Factor (vWF) followedb y
TRITC conjugated anti-rabbit. Confocal images on sections from mice injected with biotinylated class1 (A) and class2 (B) showed the localization of
these antibodies on small brain vessels structures in some cases colocalizing with vWF (class2 B). No presence of bac1 (C) scFv was detected on brain
vessels. Calibration bar=5 mm.
doi:10.1371/journal.pone.0009698.g006
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